Home Online Features Alpha Biopharma received NMPA approval for Zorifertinib Tablets (Zorifer®), the world's first EGFR-TKI for lung cancer with brain metastases.
Alpha Biopharma received NMPA approval for Zorifertinib Tablets (Zorifer®), the world’s first EGFR-TKI for lung cancer with brain metastases.
Hand-out
Press Releases
Alpha Biopharma  
November 20, 2024

Alpha Biopharma received NMPA approval for Zorifertinib Tablets (Zorifer®), the world’s first EGFR-TKI for lung cancer with brain metastases.

SHANGHAI, Nov. 20, 2024 /PRNewswire/ -- On November 20, 2024, the National Medical Products Administration (NMPA) announced on its official website that the NMPA approved the listing of Zorifertinib Hydrochloride

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social